E, Steinberger J. Metabolic syndrome and cardiovascular risk in survivors after hematopoietic cell transplantation. Bone Marrow Transplant. 2012; 47(5):619–625.45 45. Meacham LR, Chow EJ, Ness KK, et al. Cardiovascular risk factors in adult survivors of pediatric cancer‐‐a report from the childhood cancer survivor study. Cancer Epidemiol Biomarkers Prev. 2010; 19(1):170–181.
46 46. Shalitin S, Phillip M, Stein J, et al. Endocrine dysfunction and parameters of the metabolic syndrome after bone marrow transplantation during childhood and adolescence. Bone Marrow Transplant. 2006; 37(12):11091117.
47 47. Baker KS, Ness KK, Steinberger J, et al. Diabetes, hypertension, and cardiovascular events in survivors of hematopoietic cell transplantation: a report from the bone marrow transplantation survivor study. Blood. 2007; 109(4):1765–1772.
48 48. Chow EJ, Baker KS, Lee SJ, et al. Influence of conventional cardiovascular risk factors and lifestyle characteristics on cardiovascular disease after hematopoietic cell transplantation. J Clin Oncol. 2014; 32(3):191–198.
49 49. The Childhood Cancer Survivor Study: CCSS Cardiovascular Risk Calculator: St. Jude Childrens' Research Hospital. Available from: https://ccss.stjude.org/cvcalc (accessed 24 August 2020).
50 50. Kobashigawa JA, Katznelson S, Laks H, et al. Effect of pravastatin on outcomes after cardiac transplantation. N Eng J Med. 1995; 333(10):621–627.
51 51. Mahle WT, Vincent RN, Berg AM, Kanter KR. Pravastatin therapy is associated with reduction in coronary allograft vasculopathy in pediatric heart transplantation. J Heart Lung Transplant. 2005; 24(1):63–66.
52 52. Argent E, Kainer G, Aitken M, et al. Atorvastatin treatment for hyperlipidemia in pediatric renal transplant recipients. Pediatr Transplant. 2003; 7(1):38–42.
53 53. Cosio FG, Pesavento TE, Pelletier RP, et al. Patient survival after renal transplantation III: the effects of statins. Am J Kidney Dis. 2002; 40(3):638–643.
54 54. Wang GJ, Cui Q, Balian G. The Nicolas Andry award. The pathogenesis and prevention of steroid‐induced osteonecrosis. Clin Orthop Relat Res. 2000( 370):295–310.
55 55. Pritchett JW. Statin therapy decreases the risk of osteonecrosis in patients receiving steroids. Clin Orthop Relat Res. 2001( 386):173–178.
56 56. Prasad GV, Ahmed A, Nash MM, Zaltzman JS. Blood pressure reduction with HMG‐CoA reductase inhibitors in renal transplant recipients. Kidney Int. 2003; 63(1):360–364.
57 57. Prasad GV, Chiu R, Nash MM, Zaltzman JS. Statin use and bone mineral density in renal transplant recipients. Am J Transplant. 2003; 3(10):1320–1321.
58 58. Tsiara S, Elisaf M, Mikhailidis DP. Early vascular benefits of statin therapy (Review). Curr Med Res Opin. 2003; 19(6):540–556.
59 59. Fehr T, Kahlert C, Fierz W, et al. Statin‐induced immunomodulatory effects on human T cells in vivo. Atherosclerosis. 2004; 175(1):83–90.
60 60. Mach F. Statins as immunomodulatory agents. Circulation. 2004; 109(21 Suppl 1):II15–II17.
61 61. Pritchett JW. Statins and dietary fish oils improve lipid composition in bone marrow and joints. Clin Orthop Relat Res. 2007; 456:233–237.
62 62. Armenian SH, Sun CL, Kawashima T, et al. Long‐term health‐related outcomes in survivors of childhood cancer treated with HSCT versus conventional therapy: a report from the Bone Marrow Transplant Survivor Study (BMTSS) and Childhood Cancer Survivor Study (CCSS). Blood. 2011; 118(5):1413–1420.
63 63. Sudour H, Mainard L, Baumann C, et al. Focal nodular hyperplasia of the liver following hematopoietic SCT. Bone Marrow Transplant. 2009; 43(2):127–132.
64 64. Pillon M, Carucci NS, Mainardi C, et al. Focal nodular hyperplasia of the liver: an emerging complication of hematopoietic SCT in children. Bone Marrow Transplant. 2015; 50(3):414–419.
65 65. Hingorani S, Guthrie KA, Schoch G, et al. Chronic kidney disease in long‐term survivors of hematopoietic cell transplant. Bone Marrow Transplant. 2007; 39:223–229.
66 66. Hingorani S. Chronic kidney disease after liver, cardiac, lung, heart‐lung, and hematopoietic stem cell transplant. Pediatr Nephrol. 2008; 23(6):879–888.
67 67. Hingorani SR, Seidel K, Lindner A, et al. Albuminuria in hematopoietic cell transplantation patients: prevalence, clinical associations, and impact on survival. Biol Blood Marrow Transplant. 2008; 14(12):1365–1372.
68 68. Jodele S, Laskin BL, Dandoy CE, et al. A new paradigm: Diagnosis and management of HSCT‐associated thrombotic microangiopathy as multi‐system endothelial injury. Blood Reviews. 2015; 29(3):191–204.
69 69. Hingorani S. Kidney and bladder complications of hematopoietic cell transplantation. In: Forman SJ, Negrin RS, Antin JH, Appelbaum FR (eds). Thomas' Hematopoietic Cell Transplantation. 5th edn. Chichester, UK: John Wiley & Sons, Ltd; 2016 pp. 1131–1141.
70 70. Vincent F, Costa MA, Rondeau E. Chronic renal failure: a nonmalignant late effect of allogeneic stem cell transplantation (Letter to the Editor). Blood. 2003; 102(7):2695–2696.
71 71. Barnett AH, Bain SC, Bouter P, et al. Angiotensin‐receptor blockade versus converting‐enzyme inhibition in type 2 diabetes and nephropathy. N Eng J Med. 2004; 351(19):1952–1961.
72 72. Strippoli GF, Craig M, Deeks JJ, et al. Effects of angiotensin converting enzyme inhibitors and angiotensin II receptor antagonists on mortality and renal outcomes in diabetic nephropathy: systematic review (Review). BMJ. 2004; 329(7470):828.
73 73. Petryk A, Bergemann TL, Polga KM, et al. Prospective study of changes in bone mineral density and turnover in children after hematopoietic cell transplantation. J Clin Endocrinol Metab. 2006; 91(3):899–905.
74 74. Kaste SC, Shidler TJ, Tong X, et al. Bone mineral density and osteonecrosis in survivors of childhood allogeneic bone marrow transplantation. Bone Marrow Transplant. 2004; 33(4):435–441.
75 75. Sklar CA, Mertens AC, Mitby P, et al. Risk of disease recurrence and second neoplasms in survivors of childhood cancer treated with growth hormone: a report from the Childhood Cancer Survivor Study. J Clin Endocrinol Metab. 2002; 87(7):3136–3141.
76 76. Bar M, Ott SM, Lewiecki EM, et al. Bone Health Management After Hematopoietic Cell Transplantation: An Expert Panel Opinion from the American Society for Transplantation and Cellular Therapy. Biol Blood Marrow Transplant. 2020; 9:S1083–8791. doi: 10.1016/j.bbmt.2020.07.001. Online ahead of print. PMID: 32653624
77 77. Carpenter PA, Hoffmeister P, Chesnut CH III, et al. Bisphosphonate therapy for reduced bone mineral density in children with chronic graft‐versus‐host disease. Biol Blood Marrow Transplant. 2007; 13:683–690.
78 78. Kuhlen M, Bader P, Sauer M, et al. Low incidence of symptomatic osteonecrosis after allogeneic HSCT in children with high‐risk or relapsed ALL ‐ results of the ALL‐SCT 2003 trial. Br J Haematol. 2018; 183(1):104–109.
79 79. Li X, Brazauskas R, Wang Z, et al. Avascular necrosis of bone after allogeneic hematopoietic cell transplantation in children and adolescents. Biol Blood Marrow Transplant. 2014; 20(4):587–592.
80 80. Nishimura T, Matsumoto T, Nishino M, Tomita K. Histopathologic study of veins in steroid treated rabbits. Clin Orthop Relat Res. 1997( 334):37–42.
81 81.
